Supplemental Table1. Distribution of genetic variant alleles according to the response to clopidogrel
SNP Overall Response to clopidogrel
N=447 NPR(N=365) HPR(N=82) P
ABCB1(rs1045642) 0.505
CC 382(85.5%
)
310(84.9%) 72(87.8%)
CT or TT 65(14.5%) 55(15.1%) 10(12.2%)
CY2B6(rs3745274) 0.201
GG 306(68.5%
)
245(67.1%) 61(74.4%)
GT or TT 141(31.5%
)
120(32.9%) 21(25.6%)
CYP2C9(rs1057910) 0.568
AA 413(92.4%
)
336(92.1%) 77(93.9%)
AC 34(7.6%) 29(7.9%) 5(6.1%)
CYP2D6(rs3892097) 1.000
GG 442(98.9%
)
361(98.9%) 81(98.8%)
GA 5(1.1%) 4(1.1%) 1(1.2%)
CYP3A4(rs274057) 0.698
AA 436(97.5%
)
355(97.3%) 81(98.8%)
AG 11(2.5%) 10(2.7%) 1(1.2%)
P2Y12(rs2046934) 0.341
TT 319(71.4%
)
264(72.3%) 55(67.1%)
CT or CC 128(28.6%
)
101(27.7%) 27(32.9%)
CYP2C19*2 0.015
GG 207(46.3%
)
179(49.0 %) 28(34.1%)
GA or AA 240(53.7%
)
186(51.0%) 54(65.9%)
CYP2C19*3 0.011
GG 400(89.5%
)
333(91.2 %) 67(81.7%)
GA or AA 47(10.5%) 32(8.8%) 15(18.3%)
CYP2C19*17 0.376
CC 438(98.0%
)
356(97.5%) 82(98.8%)
CT 9(2.0%) 9(2.5%) 0(1.2%)
HPR=high platelet reactivity; NPR=normal platelet reactivity; SNP=single nucleotide polymorphism
Supplemental Table 2. Characteristics of the study population according to the CYP2C19 loss- of-function genotype
Characteristics Overall Number of the CYP2C19 LOF allele
N=447 0(N=176) 1(N=205) 2(N=66) P
Baseline
Age 63±10 64±10 62±11 64±11 0.354
Male 358(80.1%
)
145(82.4%) 167(81.5%) 46(69.7%
)
0.071
BMI 24.8±1.6 24.8±1.6 24.7±1.5 24.6±1.7 0.472
Hypertension 287(64.2%
)
117(66.5%) 134(65.4%) 36(54.5%
)
0.202
Diabetes mellitus 134(30.0%
)
52(29.5%) 62(30.2%) 20(30.3%
)
0.987
Hypercholesterolemia 91(21.4%) 37(21.0%) 41(20.0%) 13(19.7%
)
0.960
Current smoking 266(59.5%
)
112(63.6%) 115(56.1%) 39(59.1%
)
0.326
Stroke 32(7.2%) 16(9.1%) 12(5.9%) 4(6.1%) 0.449
Clinical presentation 0.368
STEMI 155(34.7%
)
66(37.5%) 64(31.2%) 25(37.9%
)
NSTACS 292(65.3%
)
110(62.5%) 141(68.8%) 41(62.1%
) Medication
Statin 444(99.3%
)
174(98.9%) 204(99.5%) 66(100%) 0.478
β-blocker 423(94.6%
)
166(94.3%) 195(95.1%) 62(93.9%
)
0.908
ACEI or ARB 402(89.9%
)
158(89.8%) 190(92.7%) 54(81.8%
)
0.038
PPI 126(28.2%
)
52(29.5%) 58(28.3%) 16(24.2%
)
0.716 Intervention procedure
LAD related 236(52.8%
)
96(54.5%) 102(49.8%) 38(57.6%
)
0.454
Length of stents(mm) 43.1±24.2 42.6±24.0 42.8±24.2 45.5±25.
0
0.695 Examination
CRP≥3.0mg/L 258(57.7%
)
99(56.3%) 124(60.5%) 35(53.0%
)
0.498
LVEF≤45% 28(6.3%) 10(5.7%) 13(6.3%) 5(7.6%) 0.866
Data are expressed mean±SD or number of patients (percentage).
ACEI=angiotensin-converting-enzyme inhibitor; ARB=angiotensin II receptor blocker; BMI=body mass index;
CRP=C-reactive protein; LAD=left anterior descending artery; LOF=loss-of-function; LVEF=left ventricular ejection
fraction; NSTACS includes non-ST segment elevation myocardial infarction and unstable angina pectoris;
PPI=proton pump inhibitor; STEMI=ST segment elevation myocardial infarction.
Supplemental Table 3. Effects of the CYP2C19 LOF allele on clinical outcome in unadjusted COX regression analysis
Ischemic events,n(%)
Noncarriers (N=176)
1 LOF Carriers 2 LOF Carriers
N=205 HR(95%CI) P N=66 HR(95%CI) P
Composite 7(4.0) 12(5.9) 1.508(0.594-3.830) 0.388 9(13.6) 3.644(1.357-9.787) 0.01
0 Cardiovascular death 1(0.6) 2(1.0) 1.736(0.157-
19.143)
0.653 0 0.000 0.99
0 Nonfatal MI 5(2.8) 9(4.4) 1.584(0.531-4.726) 0.410 8(12.1) 4.450(1.485-13.882) 0.00
8
Stroke 1(0.6) 1(0.5) 0.891(0.056-
14.832)
0.935 1(1.5) 2.914(0.182-46.613) 0.45 0 CI=confidence interval; HR=hazard ratio; LOF=loss-of-function; MI=myocardial infarction
